OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Waters and Genovis to Collaborate on Biopharmaceutical Characterization Workflows
Waters and Genovis will work to develop automated workflows for the fast and constant characterization of critical quality attributes of monoclonal antibodies and other protein-based drugs in bioprocess development, formulation, stability testing, and quality control.
Waters Corporation and Genovis, a US-based enzymes and technologies provider, announced on April 13, 2021 that they have entered into a collaboration to develop and market complete routine biopharmaceutical characterization workflows based on the Waters BioAccord LC–MS System, Andrew+ pipetting robot, and Genovis SmartEnzymes.
Under the terms of the agreement, the companies will work to develop automated workflows for the fast and constant characterization of critical quality attributes of monoclonal antibodies and other protein-based drugs in bioprocess development, formulation, stability testing, and quality control, Waters said in a company press release. The workflows in development will focus on product variant analysis, bioprocess stability monitoring, and biosimilar glycosylation analysis.
“Biologics analysis is an area that is ripe for improvement. What takes analytical scientists several days to do, should take hours or minutes instead,” said Jeff Mazzeo, vice-president, Global Marketing and Scientific Operations, Waters Corporation, in the press release. “Today, up-front sample preparation is a major bottleneck to productivity, largely due to the number of manual steps involved and the outmoded technology by which samples are readied for analysis. By combining Genovis’ SmartEnzymes with automation, liquid chromatography/time-of-flight mass spectrometry, and application-specific software workflows from Waters, we intend to move biotherapeutic analysis forward in ways never thought possible.”
“The BioAccord LC–MS system and the Andrew+ pipetting robot align perfectly with our strategies and vision at Genovis to bring simplified, robust, and automated enzyme-driven workflows to the biopharma industry,” added Fredrik Olsson, CEO, Genovis, in the press release. “The enzymatic workflows that we will develop in collaboration with Waters will help our customers in their efforts to bring safe and novel therapeutics to patients, faster.”
Source: Waters
Related Content:
